AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02390778 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Debriefing
Description: Group Debriefing involves story-telling, identifying emotional responses to these stories, psycho-education and practical information to normalize group member reactions to a distressing event.
Study NCT02390778 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: leisure activity (film showing)
Study NCT01716585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for ribavirin
Description: Capsule
Study NCT02582008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion Hydrochloride
Description: Given PO
Study NCT02582008 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02582008 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02582008 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Replacement
Description: Given NRT
Study NCT02582008 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02582008 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02582008 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02582008 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: Given PO
Study NCT01142011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belimumab
Description: The first cycle of Belimumab (10mg/kg by intravenous (IV) infusion) is a loading cycle of 3 doses over 28 days (days 1, 15, 29). After the first cycle, additional cycles of belimumab (10mg/kg by intravenous (IV) infusion) will be administered every 28 ± 1 days (cycle 2 and all subsequent cycles).~The infusion will be administered over a minimum period of 1 hour.
Study NCT04787146 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: Once the patient is included, a drug assessment is carried out as part of the treatment and then an compliance questionnaire is submitted to him.
Study NCT06518330 — intervention group
Intervention type: DRUG
Intervention: Intake of Methylphenidate
Description: Intake of Methylphenidate
Study NCT01142362 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VGX-3400X
Description: DNA plasmids delivered via IM injection + electroporation using CELLECTRA device
Study NCT02811367 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HPV test
Description: Women will perform the HPV self-test and will also undergo a physician-performed HPV test.
Study NCT02811640 — intervention group
Intervention type: OTHER
Intervention: Study Participants
Description: IAP will be observed and measured with a hand held Stryker Pressure Monitor during laparoscopic surgery and compared to the standard IAP measurements obtained with the insufflator at the time of PD catheter insertion
Study NCT03055806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IX-01 400 mg
Description: IX-01 400 mg caplet
Study NCT03055806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo caplet(s)
Study NCT03055806 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo caplet(s)
Study NCT03055806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IX-01 800 mg
Description: IX-01 800 mg (Two 400 mg caplets)
Study NCT03055806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IX-01 1200 mg
Description: IX-01 1200 mg (Three 400 mg caplets)
Study NCT00522652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PX-478
Description: Oral formulation, dose escalation, taken on days 1 to 5 of a 21 day cycle until progression or development of unacceptable toxicity
Study NCT02690506 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02690506 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Study NCT04464876 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SATURN TA System
Description: SATURN TA TMVR Device implanted
Study NCT03464929 — intervention group
Intervention type: DEVICE
Intervention: Airtraq indirect laryngoscopy
Description: Attempt to intubation using the Airtraq device
Study NCT03464929 — intervention group
Intervention type: DEVICE
Intervention: King Vision indirect laryngoscopy
Description: Attempt to intubation using the King Vision device
Study NCT03474991 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celestamine®
Description: Children in KIDS-STEP will be receiving either oral betamethasone (Celestamine®) or oral placebo dosed once daily for two consecutive days. Celestamine® N 0.5 liquidum is a betamethasone solution and will be used in the active comparator arm. Study medication will be administered orally once a day on two consecutive days. A standard dose of 0.1-0.2 mg/kg will be used. All doses used in KIDS-STEP fall into the range of recommended doses according to the Summary of Medical Product Characteristics.
Study NCT03474991 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Celestamine®
Description: Children in KIDS-STEP will be receiving either oral betamethasone (Celestamine®) or oral placebo dosed once daily for two consecutive days. Celestamine® N 0.5 liquidum is a betamethasone solution and will be used in the active comparator arm. Study medication will be administered orally once a day on two consecutive days. A standard dose of 0.1-0.2 mg/kg will be used. All doses used in KIDS-STEP fall into the range of recommended doses according to the Summary of Medical Product Characteristics.
Study NCT04176016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTSA101-DTPA-111In
Description: single IV injection, 185MBq/body
Study NCT04176016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTSA101-DTPA-90Y
Description: IV injection (max. 3 injections per patient), 1110MBq/body
Study NCT01482338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EE 20 microgram with desogestrel 150 mg
Description: Comparison of 2 different low-dose oral contraceptive pill which one consists of 20 microgram ethinyl estradiol and 150 mg desogestrel and the other consists of 20 microgram ethinyl estradiol and 3 mg drospirenone. Both were taken orally by participants every day beginning Day1 to Day 3 of the first menstrual cycle until complete 24 days and continued with free-hormone pills for 4 days. The next cycle has to continue in the same way until complete 6 cycles.
Study NCT01482338 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EE 20 microgram with drospirenone 3 mg
Description: Comparison of 2 different low-dose oral contraceptive pill which one consists of 20 microgram ethinyl estradiol and 150 mg desogestrel and the other consists of 20 microgram ethinyl estradiol and 3 mg drospirenone. Both were taken orally by participants every day beginning Day1 to Day 3 of the first menstrual cycle until complete 24 days and continued with free-hormone pills for 4 days. The next cycle has to continue in the same way until complete 6 cycles.
Study NCT02036008 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Liver MRI with EcGd
Description: Participants will receive a liver MRI with EcGd as per clinical institutional protocol.~Participants will receive EcGd at a dose of 0.1 mL/kg body mass up to 10 mL. This will be administered automatically using an MRI-compatible power injector, as a bolus through an intravenous line placed in an antecubital vein at a rate of 1.5 mL/s followed by 25 mL of 0.9% saline flush.~Participants will be imaged using a 3.0 T MRI scanner with an 8 channel body phased array coil utilized covering the entire liver. Images of the liver will be obtained including: axial precontrast phase, axial arterial phase, axial portovenous phase, axial 5 minute delayed phase, axial 10 minute delayed phase, axial 20 minute delayed phase. Additional noncontrast images will be obtained as per institutional protocol, including diffusion weighted imaging, in/out of phase imaging, and T2 weighted imaging.
Study NCT03391414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hypertonic bicarbonate
Description: 8.4% sodium bicarbonate inhaled
Study NCT03861832 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: KB220Z
Description: Acts to enhance dopamine
Study NCT03861832 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo that looks the same, but does not contain amino acid precursors or any active ingredients in the nutraceutical
Study NCT03397095 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CSWT+BMMSCs
Description: All participants will screened by D-SPECT to assess the myocardium viability. If the viable myocardium is detected, Patients will be randomized to receive cardiac shock wave therapy with an equipment (Modulith SLC; Storz Medical, Switzerland) followed the recommended protocol developed by Tohoku University of Japan and the protocol developed by the University of Essen, Germany. An over-the-wire catheter will be positioned in the target coronary artery and the cells resuspended in saline will be injected intracoronary.
Study NCT03397095 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: CSWT+Sham operation
Description: Patients randomized to this group will receive a routine cardiac shock wave therapy and coronary angiography. No cells will be administered via the coronary artery.
Study NCT01521494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA21
Study NCT01521494 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03434860 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: probiotic
Description: The multiprobiotic Symbiter which contains of 14 alive probiotic strains of Lactobacillus + Lactococcus (6×1010 CFU/g), Bifidobacterium (1×1010/g), Propionibacterium (3×1010/g), Acetobacter (1×106/g) genera. Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) of probiotic per day.
Study NCT03434860 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) of gel per day
Study NCT00807768 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 3-Dimensional Conformal Radiation Therapy
Description: Undergo pelvic radiation therapy
Study NCT00807768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT00807768 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo pelvic radiation therapy
Study NCT00807768 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Internal Radiation Therapy
Description: Undergo vaginal cuff brachytherapy
Study NCT00807768 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Internal Radiation Therapy
Description: Undergo vaginal cuff brachytherapy
Study NCT00807768 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00807768 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00807768 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT00807768 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT00807768 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT00807768 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT00807768 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02288663 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: measurement of morphological parameters
Description: measurement of morphological parameters : thigh perimeter, leg perimeter, arm perimeter.
Study NCT02288663 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: a blood sample
Description: One single blood sample to assay SCr (enzymatic), BUN (blood urea nitrogen), cystatin C, CRP, Na, K, Cl, albuminemia.
Study NCT02288663 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: albumin or blood in urine
Description: dipstick analysis for albumin or blood in urine
Study NCT02288663 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Dual X-ray absorptiometry (DXA)
Description: measurement of lean body mass by whole-body DXA
Study NCT02288663 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Bioelectric Impedance Spectroscopy (BIS)
Description: measurement of lean body mass by BIS
Study NCT02288663 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: 51Cr-EDTA plasma clearance
Description: measurement of 51Cr-EDTA plasma clearance to determine GFR
Study NCT01143818 — intervention group
Intervention type: DRUG
Intervention: AndroGel (testosterone gel) 1%
Description: AndroGel is topical testosterone gel 1% and is prescribed for once daily use.
Study NCT01142960 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Starch
Description: 1350mg/day
Study NCT01142960 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lycium Barbarum
Description: 1350mg/day
Study NCT02860676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cirmtuzumab
Description: cirmtuzumab, dose based on ongoing phase 1 trial, q14days x 4 doses, then q28 days x 4 doses, until disease progression.
Study NCT03484780 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VisONE ADS
Description: VisONE stimulator and leads for delivering continual Synchronized Diaphragmatic Stimulation
Study NCT01365897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil
Description: Modafinil 200mg
Study NCT01365897 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Modafinil
Description: Modafinil 200mg
Study NCT03837132 — intervention group
Intervention type: BEHAVIORAL
Intervention: Palliative care assessment
Description: Patients with advanced pancreatic cancer will have regular palliative care assessment with palliative care team
Study NCT02283203 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: APOTEL max
Description: The study drug is provided in a form of bag with 100ml final volume and it is directly connected to the infusion device that leads to a catheter already cannulated in one antecubital vein.
Study NCT01287507 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactoferrin (bovine origin)
Description: Bovine lactoferrin 200 mg/daily, given with either human milk or preterm formula
Study NCT02283203 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is provided in a form of bag with 100ml final volume and it is directly connected to the infusion device that leads to a catheter already cannulated in one antecubital vein. Placebo contains water for injection and inactive vehicles.
Study NCT00304863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactobacillus GG
Description: This arm will receive the additional probiotic of lactobacillus GG
Study NCT02837042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered intravenously every 3 weeks.
Study NCT04015674 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise group
Description: Aerobic exercise on a stationary bicycle
Study NCT04015674 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise group
Description: Aerobic exercise on a stationary bicycle
Study NCT04015674 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: In a rest
Study NCT04015674 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control group
Description: In a rest
Study NCT03033199 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic Agent
Description: probiotic capsules containing three viable and freezedried strains-Lactobacillus acidophilus,Lactobacillus casei, and Bifidobacterium bifidum：2 capsules, bid x 4 weeks for one cycle. It will be given for one or two cycles.
Study NCT03033199 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone 40 mg per day, 4 consecutive days
Study NCT01340599 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: defined green tea catechin extract
Description: Given PO
Study NCT01340599 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given PO
Study NCT01340599 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Correlative studies
Study NCT01340599 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: immunohistochemistry staining method
Description: Correlative studies
Study NCT01287507 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Lactoferrin (bovine origin)
Description: Bovine lactoferrin 200 mg/daily, given with either human milk or preterm formula
Study NCT01736176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa-Carbidopa Intestinal Gel
Description: Levodopa-carbidopa intestinal gel (LCIG) for upper-intestinal infusion is a suspension of levodopa (20 mg/mL) and carbidopa monohydrate (5 mg/mL) in an aqueous gel, administered continuously by a portable pump via a percutaneous endoscopic gastrojejunostomy (PEG-J) tube.~The rate of LCIG infusion was expected to be within the range of 1 to 10 mL/hour (20 to 200 mg of levodopa/hour) in most instances over a period of 16 consecutive hours.
Study NCT01736176 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous Endoscopic Gastrostomy with Jejunal Extension (PEG-J)
Study NCT01736176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa-carbidopa Immediate Release (LC-IR) Tablets
Description: After LCIG initiation, participants could take prescribed oral levodopa-carbidopa immediate or continuous release (i.e., oral LC prescribed by the investigator) for nighttime use.
Study NCT02409576 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Expanded , Activated NK cells
Description: 1. Chemotherapy - Each patient will receive immunosuppressive chemotherapy before infusion of NK cells.~   Day -7 Cyclophosphamide at 60mg/kg Day -6 Fludarabine at 25mg/m2 daily for 5 days~2. Radiation - Each patient will receive radiation within 48 hr of NK cell infusion to make the tumor cells more sensitive to NK cell killing Radiation 2Gy~3. Cytokine support - Each pateint will receive IL-2 to support NK cell activation and expansion in vivo Day -1 alternate day for a total of 6 doses~4. NK cells - Expanded activated haploidentical NK cells will be infused on day 0.
Study NCT03389009 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound Biomicroscopy of anterior segment of the eye
Description: 5150 Vumax (Sonomed, USA) under standard illumination
Study NCT02473354 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Remifentanil
Description: The opioid used for this study is Remifentanil and is commonly used in the operating room. Remifentanil will be given under normoxic (breathing room air \[21% Oxygen\]) and hyperoxic (breathing 50% oxygen) conditions to determine if the measurement of the specific respiratory parameters will predict the OIRD response.
Study NCT02473354 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Oxygen
Description: Remifentanil will be administered under normal oxygen (normoxia) and increased oxygen (hyperemic) conditions.
Study NCT03676712 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: scoliosis brace
Description: Wear at least 18 hours a day
Study NCT04561960 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoride toothpaste
Description: Fluoridated paste containing 1450ppm NaF
Study NCT04561960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toothpaste Product
Description: Non Fluoridated toothpaste with extract of miswak ( Dabur, miswak tooth paste)
Study NCT04561960 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Toothbrush
Description: Colgate classic clean Soft bristled toothbrushes, 19.05 x 1.27 x 1.91 cm
Study NCT04561960 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Toothbrush
Description: Colgate classic clean Soft bristled toothbrushes, 19.05 x 1.27 x 1.91 cm
Study NCT04561960 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Miswak Stick
Description: A miswak stick of 15 cm length
Study NCT02473354 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Carbon dioxide
Description: Carbon dioxide is used as part of the hypercapnia ventilatory response measurement (HCVR)
Study NCT02590939 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CEFALY Active
Description: Active external trigeminal nerve stimulation
Study NCT02590939 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: CEFALY Placebo
Description: Placebo external trigeminal nerve stimulation
Study NCT00763347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYR-619
Description: SYR-619 12.5 mg, tablets, orally, once daily for up to 12 weeks.